Lena Biosciences provides predictive toxicology services for drug discovery focused on drug-induced liver injury, a common cause of drug withdrawals from the market and drug discontinuations in clinical trials. The company markets hepatotoxicity, mitochondrial toxicity, and neurotoxicity services for drugs and chemicals based on proprietary, fit-for-purpose 3D tissue models and assays. Their exploratory microphysiological system platform uses patented synthetic hemoglobin oxygen delivery to provide human-relevant drug metabolism and predict drug activity and adverse drug reactions early in drug development. The company also offers 3D cell culture products and microphysiological systems at scale, enabling customers to run “clinical trials in a dish” and assess the drug’s efficacy or identify patients who may be at risk in clinical trials and post-marketing.